ESDPPP – European Society for Developmental Perinatal and Paediatric Pharmacology

ESDPPP is a voluntary, non-profit association representing the interests of paediatric pharmacologists around the world.

Meeting on Perinatal Asphyxia - C4C

The multistakeholder meeting on perinatal asphyxia, organized by the IMIconect4chilcren (c4c) entity will take place from 18.-19. September 2023 in Rome (and virtually). The meeting will be a hybrid, ahead of the 5th jENS (joint European Neonatal Societies). The meeting will be on invitation only, following expression of interest. International academic experts in perinatal asphyxia and neonatal preclinical research, representatives from pharmaceutical companies developing relevant assets, representatives from regulators (EMA, FDA) and patients, parents and their advocates can attend. Therefore, please apply by filling an Expression of Interest also available in the attached document (Deadline: 30 July).

More information about the meeting is available in the attached document below.

C4C MSM on Perinatal Asphyxia.pdf

Adobe Acrobat Document 356.5 KB

Download

Throwback: Prague Conference 2023

The society celebrated its 35th anniversary and 20th conference from 28-30 June in Prague hosted by president Pavla Pokorna. The meeting was success with a broad scientific program and a one-day pre-conference workshop on principles of neonatal and pediatric clinical pharmacology. This was accompanied by wonderful evening programs with classical concerts in the parliament and the Rudolfinum.

Slides, posters, abstracts as well as all photos will be provided in our "Members Only" area - have a look!

New Secretary General

The society informs about the new secretary general:

ROBERT FLINT

Robert Flint is a hospital pharmacist in the Erasmus MC - Sophia Children's Hospital with special focus on intensive care neonatology and obstetrics. His research aims to improve pharmacotherapy in (premature) neonates and around pregnancy using population pharmacokinetic-pharmacodynamic models leading to optimized dosing recommendations. Furthermore, Robert aims to bring the position of therapeutic drug monitoring to a higher level in clinical care. This includes a more extensive use of Bayesian forecasting to suggest the personalized starting dose as well as the next step of incorporating model informed precision dosing in pediatrics.

General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products - Guidance for Industry, FDA

This guidance is intended to assist sponsors of investigational new drug applications and applicants of new drug applications, biologics license applications and supplements to such applications who are planning to conduct clinical studies in neonatal populations.

This guidance provides recommendations for neonatal clinical pharmacology studies and will be useful for education and practice.

Additional tools (graphical snapshot, podcasts) can be found here:

Guidance Snapshot Pilot | FDA

FDA 2022 Neonatalguidance_7.25.22.pdf

Adobe Acrobat Document 385.7 KB

Download

COVID-19

IUPHAR is responding to the current crisis by coordinating pharmacological resources worldwide. Although most of the current research is done in adults, we believe in part it may be relevant for pediatric pharmacologists as well.

Click here for more information

Paediatric Pharmacology

Based in Ghent, Belgium, ESDPPP promotes research in developmental perinatal and paediatric pharmacology and offers a forum for dialogue between pharmacologists, clinicians, and scientists interested in the effect of medicines on the developing fetus, infant, and child.

35 years of ESDPPP

The ESDPPP celebrated its 35th anniversary in 2023. This milestone provides an important opportunity to celebrate ESDPPP’s achievements to date and to describe our future aspirations and ambitions on behalf of millions of paediatric patients worldwide.

Our aim

We aim to improve medicines for children and advance research and global access to paediatric medicines. We also advocate politically for the continued development of safe, evidence-based medications for children. In this respect, ESDPPP works closely with European Medicines Agency (EMA), International Union of Basic and Clinical Pharmacology (IUPHAR) and the World Health Organization (WHO).

Congresses

Meeting our colleagues is very important for our society. We enjoyed a wonderful congress in Prague, CZ, in June 2023 and are looking forward to our next congress, which will be held in Nijemegen (2025). We highly welcome your idea and suggestion for this event.

Join us on LinkedIn!!

We want to use LinkedIn for announcements and discussions in our field. Please check out our group page on LinkedIn and become a group member.

Our LinkedIn Group

ADC Journal

The official journal of the ESDPPP is the leading paediatric journal Archives of Disease in Childhood. It contains a Drug Therapy section which is published every 3 months.

Associations

ESDPPP is associated with a range of organizations like EMEA, IUHAR and WHO. Additional information on projects, initiatives and conferences will be available within short.

35 Years ESDPPP

In 2023 ESDPPP celebrated its 35th anniversary at the society's 20th conference in Prague, CZ. The meeting will be hosted by our new president Pavla Pokorna.